Skip to content

Comparison of Propofol and Thiopental in the treatment of refractory Status Epilepticus

Comparison of Propofol and Thiopental in the treatment of refractory Status Epilepticus

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138707231349N1
Enrollment
40
Registered
2009-05-02
Start date
2008-09-12
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy. Status epilepticus

Interventions

Intervention 1: Thiopental: 1mg/kg/hour intravenous continous infusion. Intervention 2: Propofol: 2mg/kg/hour intravenous continous infusion.
Treatment - Drugs
Thiopental: 1mg/kg/hour intravenous continous infusion
Propofol: 2mg/kg/hour intravenous continous infusion

Sponsors

Shiraz University of Medical Sciences,Vice chanceller for Research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Refractory Status Epilepticus. Exclusion criteria: hypotension, hypoxia, sepsis, liver failure, renal failure, heart disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Convulsion control. Timepoint: During admission. Method of measurement: Time (hours) to stop convulsion.;Convulsion control. Timepoint: During admission (EEG every 24 hr). Method of measurement: Time (hours) to see burst suppression appearance on EEG.

Secondary

MeasureTime frame
Complication of treatment (metabolic acidosis, fatty liver, hypoxia). Timepoint: blood gas analyses: every hour, blood chemicals: twice a day, others: every other day. Method of measurement: labratory tests.;Time of mechanical ventilation. Timepoint: During admission. Method of measurement: Time (hours) of mecahanical ventilation.;PICU stay. Timepoint: During admission. Method of measurement: Number of PICU admission days.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeedeh Haghbin

Shiraz University of Medical Sciences, Medical school

haghbins@sums.ac.ir+98 71 1647 4298

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026